Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $59.71 and last traded at $59.43, with a volume of 15673 shares trading hands. The stock had previously closed at $58.60.
Analyst Ratings Changes
Several analysts recently issued reports on the stock. Jefferies Financial Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Citigroup upped their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Wedbush increased their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Wells Fargo & Company increased their price target on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Finally, Canaccord Genuity Group increased their price target on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.86.
Check Out Our Latest Analysis on KNSA
Kiniksa Pharmaceuticals International Trading Down 0.1%
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The firm had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. During the same period in the prior year, the business posted $0.11 EPS. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. On average, analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.24 earnings per share for the current fiscal year.
Insider Transactions at Kiniksa Pharmaceuticals International
In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 58,424 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $53.71, for a total value of $3,137,953.04. Following the completion of the transaction, the insider owned 65,623 shares of the company’s stock, valued at $3,524,611.33. This trade represents a 47.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the firm’s stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the transaction, the director directly owned 12,546 shares of the company’s stock, valued at $628,554.60. This represents a 51.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 656,101 shares of company stock worth $34,172,073. 53.48% of the stock is owned by company insiders.
Hedge Funds Weigh In On Kiniksa Pharmaceuticals International
Several hedge funds and other institutional investors have recently added to or reduced their stakes in KNSA. Amundi purchased a new position in Kiniksa Pharmaceuticals International in the 1st quarter valued at approximately $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Kiniksa Pharmaceuticals International by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after buying an additional 1,002 shares during the period. Millennium Management LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares in the last quarter. Creative Planning acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at $358,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at $43,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.
Featured Stories
- Five stocks we like better than Kiniksa Pharmaceuticals International
- MercadoLibre Boldly Invests in Growth: Discount Deepens
- AI Dividend Increases: 3 Massive Winners Boosting Payouts
- Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader
- 5 Stocks Positioned to Benefit From the AI Inference Boom
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
